AdvSM |
Advanced systemic mastocytosis |
BM |
Bone marrow |
CR |
Complete remission/response |
CRh |
Complete response with partial hematologic recovery |
ECNM |
European Competence Network on Mastocytosis |
EMA |
European Medicines Agency |
FDA |
Food and Drug Administration |
HαT |
Hereditary alpha-tryptasemia |
ISM |
Indolent systemic mastocytosis |
IWG-MRT-ECN |
International Working Group-Myeloproliferative Neoplasms Research and Treatment |
MC |
Mast cells |
MCL |
Mast cell leukemia |
mIWG-MRT-ECNM |
Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment |
MR |
Major response |
PPR |
Pure pathologic response |
PR |
Partial response |
SM |
Systemic mastocytosis |
SM-AHN |
Systemic mastocytosis with an associated hematologic neoplasm |
SSM |
Smoldering systemic mastocytosis |
WHO |
World Health Organization |